PAREXEL STRENGTHENS CONSULTING EXPERTISE, ADDS SENIOR MEDICAL REGULATORY EXPERT
BOSTON, MA, October 2, 2001 — PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest biopharmaceutical outsourcing companies, today announced the addition of a new scientific leader to Worldwide Regulatory Affairs and North American Medical Services. Edward Bernton, M.D. will serve as a Senior Regulatory and Medical Consultant and will be located in Rockville, Maryland.
Dr. Bernton is Board-certified in Internal Medicine and Allergy/Immunology. He completed his residency at Tripler Army Medical Center and a Fellowship at Walter Reed Army Medical Center. Following residency and internal medicine practice, he spent 10 years as a researcher at the Walter Reed Army Institute of Research. His clinical research experience includes vaccinology, infectious disease, shock/trauma, endocrinology, neurovirology, molecular biology, autoimmunity, and immunology. Dr. Bernton also practiced clinical allergy for 5 years in the United States Armed Forces. Upon retiring from the Armed Forces, he was employed at Quintiles Inc. as Director of Clinical and Scientific Services for Rheumatology and Immunology. Immediately prior to joining PAREXEL, he served as Vice President of Medical Affairs at Analytica Therapeutics Inc. His duties at Analytica included assessment and prioritization of new drug discovery, analysis of development pathways and commercial and therapeutic potential, and management of pre-clinical development including outsourcing to CRO’s.
As a Senior Consultant at PAREXEL, Dr. Bernton will provide pharmaceutical and regulatory consulting on product development strategy for biopharmaceutical clients with special emphasis on the pre-clinical to phase l/ll transition. Additionally, he will provide scientific, medical, and clinical trials expertise, including medical monitoring, in the areas of clinical immunology, internal medicine, allergy, respiratory, and infectious diseases. He will assume responsibility for strategic medical and scientific consulting for Investigational New Drug Applications, New Drug Applications, clinical development plans, and protocols.
“Dr. Bernton’s extensive knowledge of global regulatory standards combined with his solid clinical expertise will prove advantageous to PAREXEL,” states Jonathan M. Fishbein, M.D., Vice President of North American Medical Services. “The addition of Dr. Bernton strengthens PAREXEL’s resource pool; by augmenting our staff, we continue to enhance our consultative services to clients.”
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 54 locations throughout 35 countries around the world, and has over 4,695 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the period ended June 30, 2001, as filed with the Securities and Exchange Commission.